Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Gunjan Shah

Memorial Sloan Kettering Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (11)

Gilles Salles

Lymphoma Service, Chief

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Akshay S Bedmutha

Assistant Professor

Emory University

UNITED STATES

View details

Sergio Giralt

Chief Attending, Adult BMT Service

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Leo Hansmann

GERMANY

View details

Caleb Lareau

Assistant Member

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Saad Usmani

Chief Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Sridevi Rajeeve

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Michael Jain

Associate Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES

View details

Marion Subklewe

LMU University Hospital

GERMANY

View details

Giulio Cassanello

Faculty

Ospedale San Raffaele

ITALY

View details

Nausheen Ahmed

Assistant Professor

University of Kansas Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gunjan Shah

Research Interests

Explore related searches

Articles (20)

Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma

Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel in patients with multiple myeloma

Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact

The EF1α promoter of cilta-cel drives a highly effective GZMK+ transcriptional program

Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial

CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates

Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma

Post-Transplant Pain and Paralysis: Neurologic Amyotrophy as an Atypical Cause of Shoulder Dysfunction Following Hematopoietic Stem Cell Transplant

Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort

Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma

Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma

Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis

Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma

Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma

Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B cell lymphoma

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas

Collaborators (11)

Gilles Salles

Akshay S Bedmutha

Sergio Giralt

Leo Hansmann

Caleb Lareau

Saad Usmani

Sridevi Rajeeve

Michael Jain

Marion Subklewe

Giulio Cassanello

Nausheen Ahmed

Make your next move.